{"id":"fluoropyrimidine-based-chemotherapy","safety":{"commonSideEffects":[{"rate":"30–50","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"20–40","effect":"Mucositis / stomatitis"},{"rate":"20–40","effect":"Diarrhea"},{"rate":"20–30","effect":"Nausea and vomiting"},{"rate":"10–20","effect":"Hand-foot syndrome"},{"rate":"20–30","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluoropyrimidines (such as 5-fluorouracil and its derivatives) are antimetabolites that interfere with nucleotide synthesis by inhibiting thymidylate synthase, a key enzyme in DNA synthesis. They also become incorporated into both DNA and RNA, causing direct cytotoxic damage and triggering apoptosis in rapidly dividing cancer cells. These agents are broadly used across multiple solid tumors and hematologic malignancies.","oneSentence":"Fluoropyrimidine-based chemotherapy inhibits thymidylate synthase and incorporates into DNA/RNA to disrupt cancer cell replication and survival.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:00.136Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer"},{"name":"Gastric cancer"},{"name":"Breast cancer"},{"name":"Pancreatic cancer"},{"name":"Head and neck cancer"}]},"trialDetails":[{"nctId":"NCT02758951","phase":"PHASE2, PHASE3","title":"Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Koen Rovers","startDate":"2017-06-01","conditions":"Colorectal Neoplasm, Colorectal Cancer, Colorectal Neoplasms Malignant","enrollment":358},{"nctId":"NCT07059494","phase":"PHASE4","title":"Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-06","conditions":"Hepatocellular Carcinoma","enrollment":40},{"nctId":"NCT06731478","phase":"PHASE3","title":"Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer","status":"RECRUITING","sponsor":"Daiichi Sankyo","startDate":"2025-02-27","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":726},{"nctId":"NCT06256328","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2024-01-10","conditions":"Gastric Cancer","enrollment":226},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT07427992","phase":"","title":"Real-WorlD ZolbetUximab in Patients With HER-2 Negative and CLaudin 18.2 PosItive MetastatiC AdEnocarcinoma","status":"RECRUITING","sponsor":"European Institute of Oncology","startDate":"2025-06-20","conditions":"Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":70},{"nctId":"NCT05993234","phase":"","title":"A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)","status":"RECRUITING","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2023-12-05","conditions":"HER2-positive Advanced Gastric Cancer, HER2-positive Gastroesophageal Junction Adenocarcinoma","enrollment":257},{"nctId":"NCT04813913","phase":"PHASE4","title":"VASCular Impact of Angiogenic Treatment in Patients With Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2019-05-05","conditions":"Oncology","enrollment":13},{"nctId":"NCT07334587","phase":"NA","title":"Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Allama Iqbal Medical College","startDate":"2025-09-01","conditions":"Metastatic Colorectal Carcinoma (mCRC)","enrollment":248},{"nctId":"NCT06245356","phase":"PHASE2","title":"Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-03-21","conditions":"Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma, DPD Deficiency","enrollment":73},{"nctId":"NCT07257575","phase":"PHASE2","title":"A Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2025-01-05","conditions":"Gastric Cancer Stage III","enrollment":138},{"nctId":"NCT07248020","phase":"PHASE2","title":"A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue","status":"NOT_YET_RECRUITING","sponsor":"Chang Gung Memorial Hospital","startDate":"2026-01-01","conditions":"Rectal Cancer, Locally Advanced Rectal Cancer, Radiation-Induced Enteritis","enrollment":72},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT01946854","phase":"NA","title":"Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-07-16","conditions":"Gastrointestinal Neoplasms","enrollment":30},{"nctId":"NCT04363801","phase":"PHASE2","title":"A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","status":"TERMINATED","sponsor":"Leap Therapeutics, Inc.","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastric Adenocarcinoma, GastroEsophageal Cancer","enrollment":247},{"nctId":"NCT07194616","phase":"NA","title":"Rectal Cancer CTC Trial","status":"RECRUITING","sponsor":"University Hospital Ostrava","startDate":"2025-04-01","conditions":"Rectal Cancer Patients","enrollment":120},{"nctId":"NCT05107674","phase":"PHASE1","title":"A Study of NX-1607 in Adults With Advanced Malignancies","status":"RECRUITING","sponsor":"Nurix Therapeutics, Inc.","startDate":"2021-09-29","conditions":"Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer","enrollment":345},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT05583422","phase":"","title":"Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2023-08-18","conditions":"Cancer","enrollment":16},{"nctId":"NCT06942663","phase":"PHASE2","title":"Randomized Phase II Trial Evaluating DFS in The Absence of an Adjuvant Component of Perioperative Chemotherapy in Patients With Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"Nizhny Novgorod Regional Clinical Oncology Center","startDate":"2025-04-15","conditions":"Gastric Cancer","enrollment":228},{"nctId":"NCT06888843","phase":"PHASE2","title":"Study to Evaluate the Use of Capecitabine in Monotherapy and in Combination With Oxaliplatin in Elderly Patients as Adjuvant Chemotherapy for Locally Advanced Colorectal Cancer.","status":"RECRUITING","sponsor":"Nizhny Novgorod Regional Clinical Oncology Center","startDate":"2025-02-01","conditions":"Colorectal Cancer","enrollment":160},{"nctId":"NCT03627728","phase":"PHASE2","title":"Study Maintenance Regorafenib vs Placebo, no Progression Patients After I Line Chemotherapy Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Gruppo Oncologico Italiano di Ricerca Clinica","startDate":"2018-06-13","conditions":"Gastric Cancer","enrollment":67},{"nctId":"NCT06475352","phase":"PHASE2","title":"Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-01-20","conditions":"Digestive Cancer, Colorectal Cancer","enrollment":400},{"nctId":"NCT03511963","phase":"PHASE3","title":"A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC","status":"COMPLETED","sponsor":"Shanghai Henlius Biotech","startDate":"2018-04-09","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":677},{"nctId":"NCT06275958","phase":"PHASE3","title":"DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2024-07-01","conditions":"Older Patients, Colorectal Cancer, Metastatic Cancer","enrollment":587},{"nctId":"NCT05144854","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ono Pharmaceutical Co. Ltd","startDate":"2021-11-05","conditions":"Gastric Cancer","enrollment":626},{"nctId":"NCT04680260","phase":"PHASE2","title":"OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Karen-Lise Garm Spindler","startDate":"2021-10-25","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":350},{"nctId":"NCT04931420","phase":"PHASE2","title":"Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2022-05-19","conditions":"Metastatic Cancer, Foregut Carcinoid Tumor, Gastric Adenocarcinoma","enrollment":""},{"nctId":"NCT06084897","phase":"PHASE2","title":"Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-10-16","conditions":"Esophageal Neoplasm Metastatic, Esophageal Cancer Stage IVb","enrollment":120},{"nctId":"NCT01606098","phase":"PHASE3","title":"The Role of Surgery of the Primary Tumour in Patients With Synchronous Unresectable Metastases of Colorectal Cancer","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2012-07","conditions":"Colon Cancer, Primary Tumour, Rectal Cancer","enrollment":206},{"nctId":"NCT02954536","phase":"PHASE2","title":"Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-11-03","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":37},{"nctId":"NCT04168931","phase":"PHASE2","title":"Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC","status":"TERMINATED","sponsor":"AC Camargo Cancer Center","startDate":"2020-01-01","conditions":"Gastric Cancer Stage IV","enrollment":5},{"nctId":"NCT02625610","phase":"PHASE3","title":"Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2015-12-24","conditions":"Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction","enrollment":499},{"nctId":"NCT01442649","phase":"PHASE2","title":"Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2010-12","conditions":"Colorectal Cancer","enrollment":133},{"nctId":"NCT04418895","phase":"PHASE2","title":"Neoadjuvant Therapy for Localized Rectal Adenocarcinoma","status":"WITHDRAWN","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2021-08-13","conditions":"Rectal Adenocarcinoma","enrollment":""},{"nctId":"NCT04918264","phase":"","title":"Fluoropyrimidine Tailored-dose Based on Uracil Concentration in Patients Treated for Digestive Carcinomas: Evaluation of Clinical Practice","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2020-11-02","conditions":"Digestive Carcinoma","enrollment":334},{"nctId":"NCT04915807","phase":"","title":"Real-world Data (RWD) of Ramucirumab Plus Paclitaxel","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2021-06","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":222},{"nctId":"NCT02167321","phase":"PHASE2","title":"Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2014-12","conditions":"Locally Advanced Rectal Cancer","enrollment":90},{"nctId":"NCT02579616","phase":"PHASE2","title":"Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2015-10-23","conditions":"Biliary Tract Cancer","enrollment":29},{"nctId":"NCT00983801","phase":"PHASE2","title":"Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2009-11","conditions":"Stomach Neoplasms","enrollment":58},{"nctId":"NCT03515941","phase":"EARLY_PHASE1","title":"Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers","status":"TERMINATED","sponsor":"Tannaz Armaghany","startDate":"2018-06-22","conditions":"Gastrointestinal Cancer","enrollment":6},{"nctId":"NCT04300361","phase":"","title":"Identifying Novel Variants in the DPYD Gene in Patients of Non-Western Descent","status":"UNKNOWN","sponsor":"Leiden University Medical Center","startDate":"2020-03-01","conditions":"Neoplasms","enrollment":600},{"nctId":"NCT04194957","phase":"NA","title":"Improving the Safety of Fluoropyrimidine-based Chemotherapy","status":"UNKNOWN","sponsor":"The Netherlands Cancer Institute","startDate":"2020-01-15","conditions":"Neoplasms","enrollment":1440},{"nctId":"NCT03023436","phase":"PHASE3","title":"Cytoreductive Surgery Combined With HIPEC and Chemotherapy for Gastric Cancer With Peritoneal Metastasis","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-01","conditions":"Stomach Neoplasm","enrollment":220},{"nctId":"NCT00419159","phase":"PHASE2","title":"Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2006-12","conditions":"Colorectal Cancer","enrollment":199},{"nctId":"NCT01372202","phase":"PHASE2","title":"CHFR Methylation Status Esophageal Cancer Study","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2011-06","conditions":"Esophageal Cancer","enrollment":31},{"nctId":"NCT02305615","phase":"","title":"An Observational Study of Continued Bevacizumab Plus Chemotherapy Until First Progression in Participants With Metastatic Colorectal Cancer (CRC)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-01-13","conditions":"Colorectal Cancer","enrollment":300},{"nctId":"NCT02654639","phase":"PHASE2","title":"Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Georgetown University","startDate":"2016-02","conditions":"Metastatic Colorectal Cancer","enrollment":4},{"nctId":"NCT01712347","phase":"","title":"An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-10-11","conditions":"Colorectal Cancer","enrollment":351},{"nctId":"NCT01765582","phase":"PHASE2","title":"Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2013-01-23","conditions":"Colorectal Neoplasms","enrollment":280},{"nctId":"NCT01169558","phase":"PHASE3","title":"A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":"Colorectal Cancer","enrollment":168},{"nctId":"NCT02944708","phase":"PHASE3","title":"Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Shanghai Proton and Heavy Ion Center","startDate":"2015-10","conditions":"Nasopharyngeal Carcinoma","enrollment":384},{"nctId":"NCT00454636","phase":"PHASE2","title":"A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-03","conditions":"Gastric Cancer","enrollment":158},{"nctId":"NCT01641458","phase":"PHASE4","title":"Pharmacology-driven Dosing of Fluoropyrimidines in Cancer Patients","status":"COMPLETED","sponsor":"Cantonal Hospital of St. Gallen","startDate":"2012-10","conditions":"Colorectal Cancer","enrollment":37},{"nctId":"NCT00973609","phase":"PHASE3","title":"Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2009-08","conditions":"Colorectal Neoplasms","enrollment":853},{"nctId":"NCT00700102","phase":"PHASE3","title":"A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-02","conditions":"Colorectal Cancer","enrollment":820},{"nctId":"NCT02355353","phase":"NA","title":"Evaluation of Diffusion Weighted Imaging -MRI in Patients With Resectable Liver Metastases From Colorectal Cancer","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2015-02","conditions":"Liver Metastases, Colorectal Cancer","enrollment":31},{"nctId":"NCT00879385","phase":"PHASE1","title":"KRAS Wild-type Metastatic Colorectal Cancer Trial","status":"COMPLETED","sponsor":"University of Utah","startDate":"2009-12","conditions":"Colorectal Cancer","enrollment":21},{"nctId":"NCT02005484","phase":"PHASE2","title":"A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2004-01","conditions":"Gastric Cancer","enrollment":6},{"nctId":"NCT01472419","phase":"","title":"Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2012-03","conditions":"Metastatic Esophageal Squamous Cell Carcinoma","enrollment":239},{"nctId":"NCT01238055","phase":"PHASE2","title":"Sunitinib + Docetaxel as Second-line Treatment in Gastric Cancer","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2008-11","conditions":"Advanced Gastric Cancer","enrollment":116},{"nctId":"NCT00889343","phase":"PHASE2","title":"Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer","status":"TERMINATED","sponsor":"AIO-Studien-gGmbH","startDate":"2009-03","conditions":"Colorectal Neoplasms","enrollment":101},{"nctId":"NCT01645748","phase":"PHASE2","title":"Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2008-10","conditions":"Head and Neck Cancer","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":289,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fluoropyrimidine-based Chemotherapy","genericName":"Fluoropyrimidine-based Chemotherapy","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluoropyrimidine-based chemotherapy inhibits thymidylate synthase and incorporates into DNA/RNA to disrupt cancer cell replication and survival. Used for Colorectal cancer, Gastric cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}